Nantes, the 18 may 2017 18 hours – OSE Immunotherapeutics AG (ISIN: FR0012127173; Mnémo: OSE), announced today that it will present at the forum ” Annual Immuno-Oncology : BD&L and Investment Forum “, dedicated to meetings between companies of the biotechnology, pharmaceutical, and investors in the field of immuno-oncology, which will be held on June 2, 2017 in Chicago, in conjunction with the international congress of ASCO (American Society of Clinical Oncology).
Download the free guide
Boost your gains
Dominique Costantini, ceo, OSE Immunotherapeutics, will present the Company, its recent progress and stages of growth to come. She will comment on the originality of his portfolio in immuno-oncology with, on the one hand, néoépitopes combined activating specific T lymphocytes (Tedopi® in phase 3 for registration in the lung cancer advanced), and, on the other hand, his new checkpoint inhibitor (OSE-172/Effi-DEM, selective antagonist of SIRPa in preclinical) blocking cells of the myeloid suppressive tumor-associated. These two products have a strong interest, both in combination with the ‘checkpoints’ T currently present and also in the case of exhaust this line of treatment immunological.
“Our franchise in immuno-oncology, is positioned on the specific activation of the T by néoépitopes and on the neutralization of the suppressor cells of the tumor microenvironment by a checkpoint. Tedopi® and DARE-172 are our major assets to strengthen our presence with clinicians, in particular in the United States “, declares Dominique Costantini.
Information on the holding of the presentation on June 2, 2017 :
Hyatt Centric Chicago Magnificent Mile Hotel
Tray presentation : B
Time of presentation : 11: 30 a.m.
ABOUT THE “Annual SACHS Immuno-Oncology: BD&L and Investment Forum”
This 3rd edition of the “Annual Sachs Immuno-oncology : BD&L and Investment Forum” in immuno-oncology brings together representatives from research, patient organisations, the pharmaceutical industry and biotechnology companies in order to initiate partnerships, project financing and investments. Approximately 250 participants are expected in this forum, and some thirty companies, listed or private, there will be a presentation. It is also a day of individual meetings held via a platform of making appointments online.
ABOUT DARE IMMUNOTHERAPEUTICS
Our ambition is to become one of the world leaders in immunotherapy activation and regulation
DARE Immunotherapeutics) is a biotechnology company specializing in the activation and immune regulation in immuno-oncology, autoimmune diseases and in transplantation.
The company has a balanced portfolio, with a risk profile that is diverse, ranging from the clinical phase to registration of R&D :
Immuno-oncology :
??? Tedopi®, a combination of 10 néoépitopes optimized to induce an activation response in immuno-oncology – ongoing Phase 3 registration in the lung cancer advanced in Europe and the United States, in patients with HLA-A2+ – Status orphan to the United States, Registration as provided for in 2019 – A Phase 2 study of Tedopi® in combination with a checkpoint inhibitor in NSCLC is planned in 2017.
??? DARE-172 (Effi-DEM), checkpoint of the new generation targeting cells of the myeloid suppressor via receptor SIRP-? – In preclinical in several cancer models.
In autoimmune diseases and transplantation :
??? FR104, immunotherapy antagonist of the CD28 – Results of Phase 1 positive – refers to autoimmune diseases, and transplantation – Licensed to Janssen Biotech Inc. for further clinical development.
??? DARE-127 (Effi-7), immunomodulatory receptor antagonist to interleukin-7 – preclinical in inflammatory bowel disease and other autoimmune diseases – Option license agreement with Servier for the development and commercialization of the product.
In the light of medical needs targeted, these products have a real potential blockbuster and make the company the ability to enter into global agreements at different stages of their development with major pharmaceutical players.
DARE Immunotherapeutics seeks the field of immunotherapy, a very attractive market in full expansion. The immunotherapy of cancer may represent to the year 2023, nearly 60% of treatments, compared to less than 3% at the present time* and the market is estimated is estimated to be $ 67 billion by 2018**.
There are more than 80 autoimmune diseases that represent an important market integrating of the major players in the pharmaceutical industry, with sales in excess of 10 billion euros for the main products. The medical need is still largely unfulfilled and will require the provision of new products to control the immune system’s innovative and responsive.
Download the free guide
Boost your gains
